Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance

Cell(2021)10.1016/j.cell.2021.11.004Source: DataRank Database

Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance is a research paper published in Cell (2021). On theSindex it has a DataRank of 0. It has been cited 82 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access82 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: bronzeTopics (44)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Gustavo Vasen ORCID,Michael Pablo ORCID,Xinyue Chen ORCID,Nathan Beutler ORCID,Arjun J. Kumar ORCID

Live enrichment

PubMed:26207759

National Institutes of Health

Grant: P30 AI027763

National Institutes of Health

Grant: S10 RR028962

National Institutes of Health

Grant: 3P30AI027763-12S2

UCSF-GIVI Center for AIDS research

National Institutes of Health

Grant: 5DP1DA051144-02

A Gene Drive Therapy for HIV: single-administration intervention for high-risk groups

National Institutes of Health

Grant: 1S10RR028962-01

BD FACSAria II Flow Cytometer

bronzeLicense: Elsevier Non-Commercial

publisherhttp://www.cell.com/article/S0092867421013192/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867421013192?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867421013192?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8577993

https://doi.org/10.1016/j.cell.2021.11.004

Fields of Study

0301 basic medicine03 medical and health sciences

Keywords

Male570Biomedical and clinical sciencesCoronavirusescoronavirus610Virus ReplicationMedical and Health SciencesAntiviral AgentsArticlevirus-like particleCell Linetherapeutic interfering particlesdefective interfering particlesDrug Delivery SystemsConditionedBiodefenseevolutionChlorocebus aethiopsAnimalsHumansLungVero CellsvariantsMesocricetusSARS-CoV-2intranasalCOVID-19Epithelial CellsBiological Scienceslipid nanoparticleCulture MediaCOVID-19 Drug TreatmentInfectious DiseasesEmerging Infectious DiseasesGood Health and Well BeingMedical MicrobiologyCulture Media, ConditionedRNANanoparticlesDefective Interfering VirusesDevelopmental Biology

Sustainable Development Goals

SDG 3: 3. Good health